PDF(Pubmed)
Abstract：
Previous studies have suggested that corticotroph tumours are associated with the overexpression of cyclin E and that the inactivation of cyclin-dependent kinases, which activate cyclin E, may have antisecretory and antiproliferative effects. Seliciclib, also known as R-roscovitine, is a pituitary-targeting agent shown to inhibit the growth of corticotroph tumour cells via cyclin E and retinoblastoma protein-mediated pathways. A recent study investigated the role of seliciclib in regulating biochemical parameters in a small number of patients with Cushing\'s disease, providing preliminary data on its possible therapeutic effectiveness in treating this disorder.
摘要：
以前的研究表明，促肾上腺皮质激素肿瘤与细胞周期蛋白E的过度表达以及细胞周期蛋白依赖性激酶的失活有关，激活细胞周期蛋白E，可能具有抗分泌和抗增殖作用。Seliclib,也被称为R-roscovitine,是一种垂体靶向剂，可通过细胞周期蛋白E和视网膜母细胞瘤蛋白介导的途径抑制促肾上腺皮质激素肿瘤细胞的生长。最近的一项研究调查了seliciclib在调节少数库欣病患者的生化参数中的作用，提供有关其治疗这种疾病的可能治疗效果的初步数据。
